

NAVIGATING THE EVOLVING PARADIGM IN HEART FAILURE

THE EMERGING IMPACT OF SGLT2 INHIBITION

Thursday, October 1, 2020 Virtual Symposium 4:30 PM-5:45 PM EDT

AGENDA all times EDT

4:30 PM-4:35 PM Welcome and Introductions/Pre-test

Javed Butler, MD, MPH, MBA (Activity Chair)

4:35 PM-4:50 PM A Review of Cardiovascular Outcomes Trial

(CVOT) Data: Exploring the Pivotal Link

Between T2D and HF

Suzanne V. Arnold, MD, MHA

4:50 PM-5:15 PM Stepping Beyond the Status Quo:

How SGLT2 Inhibitors are Bridging the

Chasm in Heart Failure

Javed Butler, MD, MPH, MBA

John McMurray, MD

5:15 PM-5:35 PM Revolutionizing Heart Failure Outcomes:

Meeting Complex Clinical Challenges

through Strategic Collaboration

Muthiah Vaduganathan, MD, MPH

5:35 PM-5:45 PM Conversations with the Experts/Audience Q&A/

Post-test

All Faculty

FACULTY



Javed Butler, MD, MPH, MBA Activity Chair University of Mississippi Jackson, Mississippi



Suzanne V. Arnold, MD, MHA Saint Luke's Mid America Heart Institute Kansas City, Missouri



John McMurray, MD University of Glasgow Glasgow, Scotland, UK



Muthiah Vaduganathan, MD, MPH Harvard Medical School Boston, Massachusetts

ACCREDITATION



In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credits*™. Learners should claim only the credit commensurate with the extent of their participation in the activity.





